Cargando…
The role of E-Cadherin expression in primary site of breast cancer
PURPOSE: The tumour’s ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis. METHOD: We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue fr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967771/ https://www.ncbi.nlm.nih.gov/pubmed/34510244 http://dx.doi.org/10.1007/s00404-021-06198-1 |
_version_ | 1784678902000517120 |
---|---|
author | Karsten, Nora Kolben, Thomas Mahner, Sven Beyer, Susanne Meister, Sarah Kuhn, Christina Schmoeckel, Elisa Wuerstlein, Rachel Harbeck, Nadia Ditsch, Nina Jeschke, Udo Friese, Klaus Kolben, Theresa Maria |
author_facet | Karsten, Nora Kolben, Thomas Mahner, Sven Beyer, Susanne Meister, Sarah Kuhn, Christina Schmoeckel, Elisa Wuerstlein, Rachel Harbeck, Nadia Ditsch, Nina Jeschke, Udo Friese, Klaus Kolben, Theresa Maria |
author_sort | Karsten, Nora |
collection | PubMed |
description | PURPOSE: The tumour’s ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis. METHOD: We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone receptors, Her2 Status) as well as with recurrence and survival. RESULTS: Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis in patients. CONCLUSION: This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than suppresses, development of metastasis and invasiveness. |
format | Online Article Text |
id | pubmed-8967771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89677712022-04-07 The role of E-Cadherin expression in primary site of breast cancer Karsten, Nora Kolben, Thomas Mahner, Sven Beyer, Susanne Meister, Sarah Kuhn, Christina Schmoeckel, Elisa Wuerstlein, Rachel Harbeck, Nadia Ditsch, Nina Jeschke, Udo Friese, Klaus Kolben, Theresa Maria Arch Gynecol Obstet Gynecologic Oncology PURPOSE: The tumour’s ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis. METHOD: We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone receptors, Her2 Status) as well as with recurrence and survival. RESULTS: Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis in patients. CONCLUSION: This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than suppresses, development of metastasis and invasiveness. Springer Berlin Heidelberg 2021-09-12 2022 /pmc/articles/PMC8967771/ /pubmed/34510244 http://dx.doi.org/10.1007/s00404-021-06198-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Gynecologic Oncology Karsten, Nora Kolben, Thomas Mahner, Sven Beyer, Susanne Meister, Sarah Kuhn, Christina Schmoeckel, Elisa Wuerstlein, Rachel Harbeck, Nadia Ditsch, Nina Jeschke, Udo Friese, Klaus Kolben, Theresa Maria The role of E-Cadherin expression in primary site of breast cancer |
title | The role of E-Cadherin expression in primary site of breast cancer |
title_full | The role of E-Cadherin expression in primary site of breast cancer |
title_fullStr | The role of E-Cadherin expression in primary site of breast cancer |
title_full_unstemmed | The role of E-Cadherin expression in primary site of breast cancer |
title_short | The role of E-Cadherin expression in primary site of breast cancer |
title_sort | role of e-cadherin expression in primary site of breast cancer |
topic | Gynecologic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967771/ https://www.ncbi.nlm.nih.gov/pubmed/34510244 http://dx.doi.org/10.1007/s00404-021-06198-1 |
work_keys_str_mv | AT karstennora theroleofecadherinexpressioninprimarysiteofbreastcancer AT kolbenthomas theroleofecadherinexpressioninprimarysiteofbreastcancer AT mahnersven theroleofecadherinexpressioninprimarysiteofbreastcancer AT beyersusanne theroleofecadherinexpressioninprimarysiteofbreastcancer AT meistersarah theroleofecadherinexpressioninprimarysiteofbreastcancer AT kuhnchristina theroleofecadherinexpressioninprimarysiteofbreastcancer AT schmoeckelelisa theroleofecadherinexpressioninprimarysiteofbreastcancer AT wuerstleinrachel theroleofecadherinexpressioninprimarysiteofbreastcancer AT harbecknadia theroleofecadherinexpressioninprimarysiteofbreastcancer AT ditschnina theroleofecadherinexpressioninprimarysiteofbreastcancer AT jeschkeudo theroleofecadherinexpressioninprimarysiteofbreastcancer AT frieseklaus theroleofecadherinexpressioninprimarysiteofbreastcancer AT kolbentheresamaria theroleofecadherinexpressioninprimarysiteofbreastcancer AT karstennora roleofecadherinexpressioninprimarysiteofbreastcancer AT kolbenthomas roleofecadherinexpressioninprimarysiteofbreastcancer AT mahnersven roleofecadherinexpressioninprimarysiteofbreastcancer AT beyersusanne roleofecadherinexpressioninprimarysiteofbreastcancer AT meistersarah roleofecadherinexpressioninprimarysiteofbreastcancer AT kuhnchristina roleofecadherinexpressioninprimarysiteofbreastcancer AT schmoeckelelisa roleofecadherinexpressioninprimarysiteofbreastcancer AT wuerstleinrachel roleofecadherinexpressioninprimarysiteofbreastcancer AT harbecknadia roleofecadherinexpressioninprimarysiteofbreastcancer AT ditschnina roleofecadherinexpressioninprimarysiteofbreastcancer AT jeschkeudo roleofecadherinexpressioninprimarysiteofbreastcancer AT frieseklaus roleofecadherinexpressioninprimarysiteofbreastcancer AT kolbentheresamaria roleofecadherinexpressioninprimarysiteofbreastcancer |